Myxoma Virus Optimizes Cisplatin for the Treatment of Ovarian Cancer In Vitro and in a Syngeneic Murine Dissemination Model

Myxoma Virus Optimizes Cisplatin for the Treatment of Ovarian Cancer In Vitro and in a Syngeneic Murine Dissemination Model

A therapeutic approach to improve treatment outcome of ovarian cancer (OC) in patients is urgently needed. Myxoma virus (MYXV) is a candidate oncolytic virus that infects to eliminate OC cells. We found that in vitro MYXV treatment enhances cisplatin or gemcitabine treatment by allowing lower doses...

Full description

Bibliographic Details
Main Authors: Bernice Nounamo, Jason Liem, Martin Cannon, Jia Liu
Format: Article
Language:English
Published: Elsevier 2017-09-01
Series:Molecular Therapy: Oncolytics
Subjects:
myxoma virus
MYXV
oncolytic
virotherapy
synergism
chemotherapy
M062R-null MYXV
syngeneic
ovarian cancer
immunotherapy
Online Access:http://www.sciencedirect.com/science/article/pii/S2372770517300311

Similar Items

Similar Items